UBS Group’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.24M | Sell |
288,857
-122,402
| -30% | -$2.64M | ﹤0.01% | 3830 |
|
|
2025
Q4 | $9.8M | Buy |
411,259
+243,855
| +146% | +$4.98M | ﹤0.01% | 3307 |
|
|
2025
Q3 | $2.28M | Buy |
167,404
+74,603
| +80% | +$776K | ﹤0.01% | 4826 |
|
|
2025
Q2 | $755K | Sell |
92,801
-46,546
| -33% | -$398K | ﹤0.01% | 5681 |
|
|
2025
Q1 | $1.09M | Buy |
139,347
+8,283
| +6% | +$96K | ﹤0.01% | 5210 |
|
|
2024
Q4 | $1.95M | Buy |
131,064
+45,168
| +53% | +$738K | ﹤0.01% | 4737 |
|
|
2024
Q3 | $1.31M | Buy |
85,896
+10,783
| +14% | +$170K | ﹤0.01% | 4393 |
|
|
2024
Q2 | $1.14M | Sell |
75,113
-133,616
| -64% | -$2.16M | ﹤0.01% | 4293 |
|
|
2024
Q1 | $3.94M | Buy |
208,729
+46,245
| +28% | +$800K | ﹤0.01% | 3224 |
|
|
2023
Q4 | $3.1M | Buy |
162,484
+104,947
| +182% | +$1.68M | ﹤0.01% | 3320 |
|
|
2023
Q3 | $1.03M | Sell |
57,537
-41,757
| -42% | -$839K | ﹤0.01% | 4043 |
|
|
2023
Q2 | $2.02M | Buy |
99,294
+637
| +0.6% | +$12.1K | ﹤0.01% | 3516 |
|
|
2023
Q1 | $1.8M | Buy |
98,657
+38,909
| +65% | +$744K | ﹤0.01% | 3541 |
|
|
2022
Q4 | $1.24M | Buy |
59,748
+20,052
| +51% | +$552K | ﹤0.01% | 3873 |
|
|
2022
Q3 | $1.04M | Sell |
39,696
-38,382
| -49% | -$1.02M | ﹤0.01% | 3728 |
|
|
2022
Q2 | $1.98M | Sell |
78,078
-115,801
| -60% | -$2.84M | ﹤0.01% | 3158 |
|
|
2022
Q1 | $6.12M | Buy |
193,879
+188,069
| +3,237% | +$6.3M | ﹤0.01% | 2348 |
|
|
2021
Q4 | $235K | Sell |
5,810
-15,146
| -72% | -$588K | ﹤0.01% | 5551 |
|
|
2021
Q3 | $731K | Buy |
20,956
+13,894
| +197% | +$432K | ﹤0.01% | 4449 |
|
|
2021
Q2 | $194K | Sell |
7,062
-38,352
| -84% | -$1.1M | ﹤0.01% | 5372 |
|
|
2021
Q1 | $1.27M | Buy |
45,414
+45,043
| +12,141% | +$1.57M | ﹤0.01% | 4010 |
|
|
2020
Q4 | $10K | Buy |
+371
| New | +$8.98K | ﹤0.01% | 7495 |
|
|
2020
Q3 | – | Sell |
-3,733
| Closed | -$92K | – | 8334 |
|
|
2020
Q2 | $92K | Sell |
3,733
-17,324
| -82% | -$468K | ﹤0.01% | 5367 |
|
|
2020
Q1 | $292K | Sell |
21,057
-21,814
| -51% | -$271K | ﹤0.01% | 4424 |
|
|
2019
Q4 | $433K | Buy |
42,871
+18,040
| +73% | +$152K | ﹤0.01% | 4962 |
|
|
2019
Q3 | $226K | Buy |
24,831
+19,056
| +330% | +$153K | ﹤0.01% | 5155 |
|
|
2019
Q2 | $46K | Buy |
+5,775
| New | +$57.8K | ﹤0.01% | 5996 |
|
|
2019
Q1 | – | Sell |
-13,465
| Closed | -$145K | – | 8082 |
|
|
2018
Q4 | $145K | Buy |
13,465
+11,187
| +491% | +$131K | ﹤0.01% | 5212 |
|
|
2018
Q3 | $32K | Buy |
2,278
+1,673
| +277% | +$21.3K | ﹤0.01% | 6493 |
|
|
2018
Q2 | $7K | Buy |
+605
| New | +$9.49K | ﹤0.01% | 7344 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
UBS Group's RCUS Position: Q1 2026 in Review
UBS Group reduced its Arcus Biosciences (RCUS) stake by 30% in Q1 2026, selling an estimated $2.64M and leaving 288,857 shares worth $6.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3830.
UBS Group first reported a position in RCUS in Q2 2018 and has held it in 30 quarters since. The position peaked at $9.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- UBS Group held 288,857 shares of Arcus Biosciences worth $6.24M as of Q1 2026.
- UBS Group sold 122,402 Arcus Biosciences shares in Q1 2026, an estimated $2.64M.
- Arcus Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3830 holding.
- UBS Group first reported a position in Arcus Biosciences in Q2 2018 and has held it in 30 quarters since.
- UBS Group's Arcus Biosciences position peaked at $9.8M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.